Brasília – Brazil’s pharmaceutical industry continues to expand in both volume and revenue. In the first half of 2025, domestic manufacturers sold 5.7 billion units — a 5% increase from the same period in 2024 and a 19% rise compared to 2021, according to ALANAC, based on data from IQVIA and the Ministry of Health.

The country’s regulatory capacity has also matured, with over 17,000 products registered with Anvisa in 2025. From 2000 to 2025, sales per capita grew by 180%, while population increased by around 29%. Today, eight out of every ten medications sold in Brazil are domestically produced — a significant shift from 25 years ago, when national and multinational products shared the market equally.

Market value followed suit: pharmaceutical sales reached BRL 138.3 billion in H1 2025, up 11.5% from H1 2024. Local labs accounted for BRL 80.2 billion (57.9%) of this total. Generics led the growth, increasing from 1.9 to 2.0 billion units; generics’ revenue rose from BRL 17.5 billion to BRL 19.3 billion. Similar and reference medicines also saw notable gains.

Over the past five years, from 2021 to 2025, Brazil’s pharmaceutical market grew from 4.8 to 5.7 billion units — a nearly one billion unit increase. In value terms, the market surged from BRL 85.1 billion to BRL 138.3 billion — a growth of over 60%. Domestic industry played a key role, rising from BRL 50.8 billion to BRL 80.2 billion in sales.

ALANAC projects that by 2030, as around 1,500 drug patents expire, Brazilian companies could produce nine out of every ten medications sold in the country. This shift underscores the national industry’s strategic role in ensuring access, innovation, and public health sustainability.

Source: Medicina S/A

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com